Enhanced Benzathine Analogs for Inflammatory Disorder Treatment

The inventive concept discloses novel benzathine analogs and systems that improve the treatment of inflammatory disorders, enhancing bioavailability, reducing sepsis onset, and combating antibiotic resistance.

The original patent's benzathine analogs demonstrated effectiveness in treating inflammatory disorders, but limitations included variable bioavailability, potential for sepsis onset, and risk of antibiotic resistance. The new inventive concept addresses these limitations by introducing carrier agents, diagnostic tools, and co-administered antibiotics to enhance treatment outcomes.

The new claims introduce a system comprising a benzathine analog and a carrier agent, which enhances bioavailability by at least 20%. A method for reducing sepsis onset involves administering the benzathine analog and monitoring cytokine levels to adjust dosage. A pharmaceutical composition for treating pneumonia combines the benzathine analog with an antibacterial agent. A system for personalized treatment utilizes a diagnostic tool to determine cytokine profiles and recommend dosages. Finally, a method for reducing antibiotic resistance co-administers the benzathine analog with an antibiotic.

The new claims provide a novel combination of benzathine analogs with carrier agents, diagnostic tools, and antibiotics, which enhances treatment outcomes and addresses the limitations of the original patent. The inventive step lies in the integration of these components to achieve improved bioavailability, reduced sepsis onset, and decreased antibiotic resistance.

Alternative embodiments may include different carrier agents, diagnostic tools, or antibiotics. Variations could involve adjusting the dosage or administration schedule of the benzathine analog, or using different benzathine analogs with varying potency.

The enhanced benzathine analogs and systems have significant commercial potential in the treatment of inflammatory disorders, particularly in the areas of sepsis and pneumonia. The target market includes pharmaceutical companies, hospitals, and research institutions focused on developing innovative treatments for these disorders.